COMMUNIQUÉS West-GlobeNewswire
-
Liposoma Technology Strengthens Its Position as a Reference Partner for Advanced Lipid-Based Delivery Systems in Europe
23/02/2026 -
Andrzej Lewandowski of Dempster Therapeutic Services Receives Prestigious 2026 ZocDoc Patient Choice Award
23/02/2026 -
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
23/02/2026 -
Bicara Therapeutics to Participate in Upcoming Investor Conferences
23/02/2026 -
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
23/02/2026 -
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026
23/02/2026 -
J-Star Signs Exclusive Distribution Agreement with PSSB
23/02/2026 -
PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data
23/02/2026 -
Solana Company (NASDAQ: HSDT) Announces Plan for the Pacific Backbone, a High-Speed Infrastructure Buildout for Solana
23/02/2026 -
Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board
23/02/2026 -
Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution
23/02/2026 -
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
23/02/2026 -
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer
23/02/2026 -
Prenetics Launches IM8 Daily Ultimate Essentials PRO — A Clinical Formula with Two New Flavours
23/02/2026 -
Blue Genes Partners with RxSense to Deliver Actionable PGx at the Point of Adjudication
23/02/2026 -
Biotech Breakthroughs, Big Buyouts, Immunotherapy Momentum, and a Media Megamerger
23/02/2026 -
Coherus Oncology to Participate in Upcoming Investor Conferences
23/02/2026 -
Transactions in Connection with Share Buy-back Program
23/02/2026 -
ICU Medical to Participate in Upcoming Investor Conferences
23/02/2026
Pages